Cargando…
A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM)
Objectives: Infliximab (IFX) is widely used in patients with refractory Takayasu arteritis (TAK). Recently, the IFX-biosimilar CT-P13 has been introduced for the treatment of inflammatory diseases. The aim of this study was to assess the efficacy and safety of CT-P13 in patients with refractory TAK....
Autores principales: | Campochiaro, Corrado, Tomelleri, Alessandro, Sartorelli, Silvia, Sembenini, Camilla, Papa, Maurizio, Fallanca, Federico, Picchio, Maria, Cavalli, Giulio, De Cobelli, Francesco, Baldissera, Elena, Dagna, Lorenzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502860/ https://www.ncbi.nlm.nih.gov/pubmed/34646844 http://dx.doi.org/10.3389/fmed.2021.723506 |
Ejemplares similares
-
Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis
por: Tomelleri, Alessandro, et al.
Publicado: (2022) -
Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey
por: Tomelleri, Alessandro, et al.
Publicado: (2020) -
Impact of Geographic Location on Diagnosis and Initial Management of Takayasu Arteritis: A Tale of Two Cohorts from Italy and India
por: Misra, Durga Prasanna, et al.
Publicado: (2022) -
Chromogranin-A production and fragmentation in patients with Takayasu arteritis
por: Tombetti, Enrico, et al.
Publicado: (2016) -
Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis
por: Tombetti, Enrico, et al.
Publicado: (2014)